{
    "nctId": "NCT02119715",
    "briefTitle": "A Phase II Study Comparing Pegylated rhG-CSF\uff08HHPG-19K\uff09 and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy",
    "officialTitle": "A Phase II Study Comparing Pegylated rhG-CSF\uff08HHPG-19K\uff09 and rhG-CSF as Supportive Therapy to Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Neutropenia, Febrile Neutropenia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 182,
    "primaryOutcomeMeasure": "Incidence and the duration of grade 3/4 neutropenia in cycle 2 and the time frame of ANC recovery to 2.0\u00d7109/L",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathology diagnosis of breast cancer,Chemotherapy na\u00efve\n* ECOG performance status 0-1\n* Age 18 to 70 years\n* Available for at least 2 cycles of consistent neoadjuvant/adjuvant therapy\n* White blood cell \u2265 4.0\u00d7109/L; absolute neutrophil count \u22652.0 \u00d7 109/L; platelet count \u2265 100 \u00d7 109/L\n* Alanine aminotransferase \u22641.5\u00d7ULN; aspartate aminotransferase \u22641.5\u00d7ULN; serum creatinine \u22641.5\u00d7ULN\n* No obvious cardiac dysfunction\n\nExclusion Criteria:\n\n* Prior bone marrow or stem cell transplantation\n* Received systemic antibiotics treatment within 72 h of chemotherapy\n* Other disease might have influence on bone marrow function\n* Radiation therapy within 4 weeks of randomization into this study\n* Previous exposure or or allergic to Pegylated rhG-CSF\n* Pregnancy, lactation",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}